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Abstract
Restoration of the tumor-suppression function by gene transfer of the melanoma differentiation-
associated gene 7 (MDA7)/interleukin 24 (IL-24) successfully induces apoptosis in melanoma
tumors in vivo. To address the molecular mechanisms involved, we previously revealed that MDA7/
IL-24 treatment of melanoma cells down-regulates interferon regulatory factor (IRF)-1 expression
and concomitantly up-regulates IRF-2 expression, which competes with the activity of IRF-1 and
reverses the induction of IRF-1–regulated inducible nitric oxide synthase (iNOS). Interferons (IFNs)
influence melanoma cell survival by modulating apoptosis. A class I IFN (IFN alfa) has been
approved for the treatment of advanced melanoma with some limited success. A class II IFN (IFN
gamma), on the other hand, supports melanoma cell survival, possibly through constitutive activation
of iNOS expression. We therefore conducted this study to explore the molecular pathways of MDA7/
IL-24 regulation of apoptosis via the intracellular induction of IFNs in melanoma. We hypothesized
that the restoration of the MDA7/IL-24 axis leads to upregulation of Class I IFNs and induction of
the apoptotic cascade. We found that MDA7/IL-24 induces the secretion of endogenous IFN beta,
another class I IFN, leading to the arrest of melanoma cell growth and apoptosis. We also identified
a series of apoptotic markers that play a role in this pathway, including the regulation of tumor
necrosis factor–related apoptosis-inducing ligand (TRAIL) and Fas-FasL. In summary, we described
a novel pathway of MDA7/IL-24 regulation of apoptosis in melanoma tumors via endogenous IFN
beta induction followed by IRF regulation and TRAIL/FasL system activation.
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Introduction
Melanoma differentiation-associated gene 7 (Mda-7)/interleukin 24 (IL-24), an IL-10 cytokine
family member, has a growth-inhibitory effect on many human cancers, including melanoma.
The overexpression of MDA7/IL-24 via adenovirus-mediated gene (Ad-mda7/IL-24) delivery
has been reported to induce apoptosis selectively in cancer cells but not in normal cells [1–4].
The mechanism of cancer cell apoptosis in response to the viral transduction of MDA7/IL-24
is partly understood and has been reported in cell lines derived from breast cancer, melanoma,
lung cancer, and other solid tumors [1–3,5–7]
Briefly, Ad-mda7 transduction of tumor cells results in profound changes in
posttranscriptionally regulated signaling pathways. In melanoma cells, Ad-mda7 transduction
of tumor cells results in up-regulation of growth arrest and DNA damage (GADD) proteins,
and the proapoptotic protein BAX [8]. This might further induce down-regulation of inducible
nitric oxide synthase (iNOS) via modulation of the interferon regulatory factor (IRF)-1/IRF-2
balance [9]. In lung cancer cells, Ad-mda7 activates protein kinase regulated by RNA (PKR),
signal transducers and activator of transcription 3 (STAT3), Jun N-terminal kinase (JNK), and
p38 mitogen-activated protein kinase (p38 MAPK). In ovarian cancer cells, Fas activation is
a critical mediator of tumor cell death, and the inhibition of this pathway blocks apoptosis
[10]. In melanoma cells, p38 MAPK inhibitors reduce Ad-mda7-mediated cell killing (4].
Together these findings indicate that the pathways mediating Ad-mda7 toxicity vary from one
tumor cell type to another.
In more recent studies [11–13], transfection with specific receptor subunits and binding assays
with MDA7/IL-24 protein identified two distinct receptors: IL-20R1/IL-20R2 (i.e., type 1
IL-20 receptors) and IL-22R1/IL-20R2 (i.e., type 2 IL-20 receptors). The maximum binding
activity for MDA7/IL-24 and the activation of MDA7/IL-24 signaling pathways were detected
only when cells were transfected with a combination of type 1 and type 2 IL-20 receptors,
indicating that these receptor complexes can mediate MDA7/IL-24 signal transduction [11–
13].
A particularly active area of research is the molecular pathways used by MDA7/IL-24 protein
for the induction of apoptosis. We previously reported that MDA7/IL-24 treatment of
melanoma cells down-regulates IRF-1 expression and concomitantly up-regulates IRF-2
expression, which competes with the activity of IRF-1 and reverses the induction of IRF-1–
regulated iNOS expression [9]. The transduction of active forms of IRFs modulates apoptotic
and antitumor properties, possibly leading to novel antitumor effector functions. It is now
known that IRFs are directly involved in the transcriptional induction of tumor necrosis factor
(TNF)–related apoptosis-inducing ligand (TRAIL), a key player in the apoptosis pathway
[14].
Apoptosis could be executed via two main pathways that lead to the activation of caspases: the
death receptor (DR) and the mitochondrial pathways [15]. The DR pathway is activated by
ligation of members of the TNF family, such as the Fas ligand (FasL), TNF-α, and TRAIL, to
DRs on the plasma membrane. The receptors of these ligands, Fas, TNF receptor 1, and DR4/
DR5, are members of the TNF receptor superfamily, characterized by similar cysteine-rich
extracellular domains and homologous cytoplasmic death domains [16]. Binding of these DRs
by their respective ligands recruits the adaptor proteins Fas-associated death domain (FADD)
and caspase-8 to the death-inducing signaling complex, triggering the proteolytic activation of
caspase-8. Caspase-8 in turn activates the effector caspases, such as caspase-3, and triggers the
proteolytic targeting of key apoptotic or cell-cycle regulatory proteins.
On the whole, interferons (IFNs) influence cell survival by modulating apoptosis. The biologic
effects of IFNs are primarily mediated via the activation of the Janus kinase (JAK)/STAT
Ekmekcioglu et al. Page 2
Cytokine. Author manuscript; available in PMC 2009 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
pathway and the subsequent induction of IFN-stimulated genes. IFNs were originally identified
by their role in viral infections. A wide variety of effects have subsequently been described,
such as antiviral, antitumor, immunomodulatory, and antiproliferative activities.
The three main types of IFNs are IFN alfa, IFN beta, and IFN gamma. IFN alfa and IFN beta
are class I IFNs, and mitogen-induced IFN gamma is a class II IFN, which uses distinct
receptors to mediate cellular responses. Since antitumor activity is the major function of class
I IFNs, they have been used extensively against various types of cancer in clinical trials, either
as monotherapy or combined with chemotherapeutic agents. However, the exact mechanisms
of class I IFNs, including the induction of apoptosis, are not yet fully understood.
Early events in class I IFN signaling include tyrosine phosphorylation of the receptor subunits
and activation of the receptor-associated Tyk-2 and Jak-1 Janus kinases, followed by the
phosphorylation of STAT proteins (JAK/STAT pathway). The activation of signaling cascades
downstream from these proteins includes IRFs. Recent extensive studies have demonstrated
that IRFs play an important role in a wide spectrum of IFN responses [17]. IRF-1 and IRF-2
have been involved in most studies because IRF-1 acts as a transcriptional activator for class
II IFNs and IFN-inducible genes, whereas IRF-2 represses the action of IRF-1 and competes
with its actions.
We previously reported that MDA7/IL-24 treatment of melanoma cells down-regulates IRF-1
expression and concomitantly up-regulates IRF-2 expression [9]. We therefore conducted the
current study to explore the molecular pathway regulated by IFNs and its role in melanoma
cell survival. We hypothesized that the regulation of gene expression in melanoma cells
activated by class I IFNs results in antitumor effects MDA7/IL-24 is the key cytokine to trigger
the up-regulation of class I IFNs. To gain insight into these mechanisms, we investigated the
differential IFN signaling pathways, focusing particularly on apoptosis-inducing pathways by
MDA7/IL-24 in melanoma cell lines.
Material and Methods
Cell Culture
We obtained two metastatic melanoma cell lines, A375 and MeWo, from the American Type
Culture Collection (Rockville, MD). Normal human epidermal melanocytes (NHEM) were
obtained from Clonetics (San Diego, CA) and cultured with the manufacturer’s human
melanocyte growth medium. Melanoma cell lines used in this study were maintained in RPMI
1640 medium supplemented with 10% fetal bovine serum, 100 U/mL of penicillin, 100 mg/
mL of streptomycin, 2 mM L-glutamine, and HEPES buffer (all from Life Technologies, Inc.,
Grand Island, NY). Cells were either treated with purified MDA7/IL-24 at 100 to 200 ng/mL
or cocultured with stably transfected HEK 293 cells at 1:1 or 1:2 dilutions with the target
melanoma cells.
Reagents
Anticaspase-3, -8, -9; PARP; PI3K p85 rabbit polyclonal antibodies (Cell Signaling
Technology, Inc, Beverly, MA) were used for Western blotting. Affinity-purified polyclonal
rabbit antibodies to MDA7/IL-24 were provided by Introgen Therapeutics (Houston, TX).
Anti-Fas and FasL mouse monoclonal antibodies were purchased from BD BioSciences (San
Jose, CA). Goat polyclonal antibody (anti-DR5) to TRAIL–receptor 2 (TRAIL-R2 or DR5)
was from Alexis Biochemicals (San Diego, CA), and rabbit polyclonal antibody (anti-DR4)
to TRAIL–receptor 1 (TRAIL-R1 or DR4) was from ProSci Inc. (Poway, CA). The same
antibodies were used for both Western blotting and immunohistochemistry studies. Preimmune
normal mouse IgG (Vector Laboratories, Burlingame, CA) was used as a negative control.
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Antivimentin antibody (BioGenex Laboratories, San Ramon, CA) was used as a positive
control for all melanoma staining. Recombinant proteins of IFN alfa and IFN gamma were
purchased from eBioscience (San Diego, CA), and IFN beta-1a was purchased from PBL
Biomedical Laboratories (Piscataway, NJ).
Purification of Human MDA7/IL-24
As we described in a recent publication [18], the full-length cDNA of mda7/IL-24 was cloned
into the pCEP4 FLAG vector (Invitrogen Corporation, Carlsbad, CA) containing the CMV
promoter. The plasmid was transfected into HEK 293 cells, and stable subclones were isolated
using 0.4 mg/mL of hygromycin. The supernatant containing the secreted MDA7/IL-24 was
supplemented with protease inhibitors (1 mg/mL of leupeptin, 1 mg/mL of pepstatin, and 0.5
mM phenylmethylsulfonyl fluoride) and 0.05% sodium azide and was concentrated 10-fold
with an Amicon stirred cell (Amicon, Beverly, MA) on a YM10 membrane. Ten-milliliter
aliquots of concentrated supernatant were separated over an S200 Superdex prep grade column
(Amersham Pharmacia Biotech, Piscataway, NJ) in 1× PBS; pH 7.4, and fractions containing
MDA7/IL-24 on Western blotting and enzyme-linked immunosorbent assay (ELISA) were
pooled.
After buffer exchange on an Amicon stirred cell to 50 mM 4 morpholinepropanesulfonic acid
(pH 6), a second purification step was performed using an Bio-Rad S column (BioRad Lab,
Hercules, CA). Column conditions consisted of a 0–to 90-mM NaCl gradient, a 5-min hold at
90 mM NaCl, a 30-min 90- to 250-mM gradient at 1 mL/min, and a 5-min hold at 250 mM
NaCl. The entire purification process was conducted at 4°C, and MDA7/IL-24 was identified
using ELISA and Western blotting. The final samples contained at least 300 ng/mL of MDA7/
IL-24 as determined by ELISA. Individual lots of partially purified MDA7/IL-24 were tested
for endotoxin using the QCL-1000 quantitative chromogenic limulus amebocyte lysate (LAL)
kit (BioWhittaker, Inc., Walkersville, MD). In some cases, further purification of IL-24 was
performed with immunoaffinity and cation exchange purification. Two affinity-enriched lots,
approximately 50 mg each and at 30% to 40% purity, were exchanged into 0.1 M NaPO4 (pH
5.0) containing 0.5 M NaCl. The semipure protein was bound to a cation exchange column
(BioRad Lab) and then eluted at 1 M NaCl. The MDA7/IL-24–containing fractions were
pooled, and bovine serum albumin was added to a final concentration of 0.1 mg/mL, to lots
used in the functional assays.
Coculturing of Melanoma Cells with MDA7/IL-24-Transfected HEK 293 Cells
Stably transfected HEK 293 cells used for production were also used for Transwell experiments
so that the effect of protein manipulation could be eliminated. These HEK 293 cells were plated
into the top wells of Transwell inserts in 6-well plates (BD Labware, Franklin Lakes, NJ) at
the same concentration, and a 5× concentration of melanoma cells was placed in the bottom
chambers. The inserts were incubated for 1 to 5 days. Cell concentrations were based on the
length of incubation time and ranged from 2.5 × 103 to 1 × 105.
Cell Viability and Apoptosis Assays
Cell viability was determined by the trypan blue exclusion assay. At previously designated
times, cells were harvested by trypsinization, and a small aliquot was suspended in a 1:10
volume with 0.1% trypan blue (Gibco BRL, Grand Island, NY). Total cell numbers and cell
viability counts were assessed by using a hemacytometer under light microscopy. We used the
ApoAlert Annexin V–FITC kit (Clontech, Mountain View, CA) to analyze cells for apoptosis.
Briefly, melanoma cells (105 to 106 cells total) were washed extensively in PBS and then
incubated with Annexin V–FITC reagent for 30 min on ice. Cells were then washed with PBS
and processed by flow cytometric analysis with use of a FACScan flow cytometer (BD
Biosciences). Assays were performed two or three times.
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Cell-Cycle Analysis
We performed cell-cycle staging by using propidium iodide (PI) staining to evaluate DNA
content. For identifying cells at different stages of the cell cycle, untreated, immunoaffinity-
purified, and immunoaffinity/cation exchange–enriched MDA7/IL-24–treated melanoma cells
were prepared as a single-cell suspension of 1 × 106 cells/mL in PBS. After the cells were fixed
with cold 70% ethanol for 2 h, they were centrifuged and then washed twice with PBS. They
were next stained with PI solution (Boehringer Mannheim, Indianapolis, IN) to a final
concentration of 5 mg/mL of PI to 10 mg/mL of RNase. We analyzed DNA content and cell-
cycle phases with a FACScan flow cytometer (BD Biosciences).
ELISA
MeWo cells were cultured in supplemented RPMI-1640 medium (Invitrogen) at 5 × 105 cells/
mL, with MDA7/IL-24 added at designated concentrations. At indicated times, we harvested
supernatants and determined the IFN beta content with an ELISA test kit (R&D Systems, Inc.,
Minneapolis, MN) according to the manufacturer’s protocol. Reference standards for ELISA
were resuspended in a cell culture medium. The amounts of IFN beta were quantified on the
basis of a standard curve after optical density was measured at 450 nm with a reference of 550
nm on an ELISA reader (Dynex Technologies, Chantilly, VA). The mean values at each time
point were then used directly for the analysis reported.
Cytochemical Analysis
Cytochemical labeling was performed on the slides of the melanoma and normal control cells
previously prepared as Cytospins. Cells were prepared as single-cell suspensions of 1 × 106
cells/mL in PBS with 1% bovine serum albumin, and 1 × 105 cells were used for each slide.
Next, slides were quickly fixed (within seconds) in acetone at room temperature. For staining,
slides were fixed again in −20°C acetone for 20 min. Next, slides were washed with distilled
water for 5 min and covered with 3% hydrogen peroxide (Sigma Chemical Co., St. Louis, MO)
in methanol to block endogenous peroxidase activity. All incubations were carried out at room
temperature in a humidified covered slide chamber.
We washed the slides in PBS before incubating them in PBS containing 0.05% Triton X-100
(Sigma Chemical Co.) for 15 min to permeabilize the cells. We then used an avidin-
biotinperoxidase complex kit (Vectastain; Vector Laboratories) to detect staining. After the
slides were incubated for 30 min with the blocking serum, we added primary antibodies at
various dilutions (1:100 to 1:200) and then incubated the slides for 60 min at room temperature.
The slides were then washed, incubated for 30 min with secondary biotinylated antibody,
washed again, and then incubated for 30 min with the avidin-biotinperoxidase complex reagent.
After the slides were washed in PBS, the immunostaining was developed by using 3-amino-9-
ethylcarbazole as a chromogen for 15 min. Slides were counterstained with hematoxylin
(Vector Laboratories) and mounted with Aqua-Mount (Lerner Laboratories, Pittsburgh, PA).
For each sample, vimentin and its isotype-matched control IgG served as positive and negative
primary antibody controls, respectively.
Immunoblotting Assays
We rinsed 2 × 106 of the indicated melanoma cells twice in ice-cold PBS and lysed them for
10 min on ice in 60 mL of lysis buffer (25 mM Tris, 140 mM NaCl, and 1% NP40 [pH 7.5])
containing 5 mM EDTA, 0.2 mM orthovanadate, 10 mM NaF, leupeptin, aprotinin, and
phenylmethylsulfonyl fluoride. Equal amounts of total protein (measured with DC Protein
Assay Reagent; BioRad Lab) were loaded on a standard-percentage SDS polyacrylamide gel,
and fractionated proteins were electroblotted onto a nitrocellulose membrane. These
membranes were blocked for 1 h at room temperature using 5% dry milk in 1× PBS and washed
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three times for 5 min each in PBS containing 0.05% Tween 20 at room temperature. The
membranes were incubated overnight at 4°C in a sealed bag with a 1:1000 dilution of all
antibodies in 10 mL of 5% dry milk/0.1% Tween 20 in 1× PBS. The membranes were then
washed three times for 5 min each in PBS containing 0.05% Tween 20 and then incubated with
peroxidase-conjugated antirabbit IgG secondary antibody (BD Biosciences) at a 1:2000
dilution in PBS with 5% dry milk and 0.1% Tween 20 for 45 min at room temperature. The
blots were visualized using an enhanced chemiluminescence detection kit (Amersham
Pharmacia Biotech).
Gene Expression Array Analysis
To screen major molecular differences between MDA7/IL-24–treated and nontreated
melanoma, we used the GEArray Q Series for Apoptosis and the Signal Transduction Pathways
gene array kits (SuperArray Bioscience Corp., Frederick, MD). Genes identified by the array
technology were also confirmed by Western blot analysis. RNA samples from the MeWo cells
were obtained by standard methods and by a new probe-labeling method, TrueLabeling-RT,
performed according to manufacturer’s guidelines (SuperArray Bioscience Corp.). This new
method reduces false-positive results (reportedly up to 90%) by eliminating RNA self-priming,
which often occurs in conventional RT labeling. The array required 1 to 5 mg of RNA, and
probes were labeled with phosphorus 32–labeled deoxycytidine 5'-triphosphate for radioactive
detection. After the overnight hybridization procedure with the membrane, the x-ray film was
washed, blocked, and exposed. The raw data were collected from the raw image by using a
scanner and ImageQuant software (Molecular Dynamics, Inc., Sunnyvale, CA) and analyzed
with use of GEArray analyzer software (SuperArray Bioscience Corp.) for preparing data
tables and graphs.
Statistical Analysis
We determined means and SDs for the variables and used the Student’s t test to evaluate the
statistical significance of the experimental results. All experiments were performed at least
three times unless otherwise indicated. Statistical significance was set at P < 0.05.
Results
Immunoaffinity and Cation Exchange Purification of MDA7/IL-24
Immunoaffinity purification of MDA7/IL-24 with monoclonal anti–MDA7/IL-24, followed
by silver staining of SDS-PAGE analysis, detected proteins at 18.5, 23, 27, 29, and 32 kDa
and a larger positive area at ~66 kDa (Fig. 1A, lane 2). Four of these bands [18.5, 23, 27, and
32 kDa) were consistent with those in the MDA7/IL-24 immunoblots. After cation exchange
purification of this affinity-purified material, only two of these proteins were further enriched
and identified by immunoblotting and silver staining (Fig. 1B, lanes 1–4). We used both
immunoaffinity and immunoaffinity/cation exchange–enriched MDA7/IL-24 protein
preparations to perform MDA7/IL-24 function studies as indicated in the specific experiments.
Affinity-Purified MDA7/IL-24 Induced Cell Death and Apoptosis in Melanoma Cells via Ligand
Binding to Type 1 IL-20R
To evaluate the biologic effects of MDA7/IL-24 treatment on melanoma cells, we investigated
cell killing by using trypan blue exclusion assays and apoptosis by Annexin V staining in
various melanoma lines (Fig. 2A). MDA7/IL-24 treatment induced cell killing and apoptosis
at various levels in all cell lines. However, the most notable killing and apoptosis were observed
in MeWo cells (53.5%) and A375 cells (45%) (Fig. 2A). Both killing and apoptosis occurred
in a dose-dependent fashion (Fig. 2B), and the treatment of melanoma cells with neutralizing
monoclonal anti–MDA7/IL-24 antibody significantly inhibited killing and apoptosis in MeWo
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cells (P =0.01). No significant decrease in cell death was observed in MeWo cells treated with
nonspecific IgG (data not shown).
These results indicate that our purified MDA7/IL-24 preparation induced a direct and specific
cytotoxic effect in melanoma cells. To determine whether MDA7/IL-24 induced cell killing
and apoptosis regulated by IL-20R1 (common receptor), we first treated MeWo cells with 50
to 100 ng/mL of anti–IL-20R1 antibody. After the cells were incubated with anti–IL-20R1
antibody for 1 h, we added 50 to 200 ng/mL of recombinant MDA7/IL-24 and cultured the
cells for up to 5 days.
No significant cell death was induced by cells exposed to anti–IL-20R1 (Fig. 2B), but up to
34% of the cells died after treatment with 200 ng/mL of recombinant MDA7/IL-24. Moreover,
cotreatment of MeWo cells with anti–IL-20R1 antibody followed by MDA7/IL-24 protein
inhibited both killing and apoptosis. Our previously published results showed that MDA7/
IL-24–induced apoptosis correlated with the expression of MDA7/IL-24 receptors (IL-20R1/
IL-20R2 or IL-22R1/IL-20R2) in these cells [19]. Together, these data strongly suggest that
MDA7/IL-24 induces cytotoxicity through IL-20R1 engagement, which eventually leads to
the death of melanoma cells.
Secreted MDA7/IL-24 Protein from Transfected HEK-293 Cells Induced Death in Melanoma
Cells
Secreted MDA7/IL-24 protein from stably transfected HEK-293 (293M) cells was used in
Transwell studies as an independent protein source. To determine whether coculturing of
melanoma cells with 293M cells induces cell death at levels comparable to those seen with
MDA7/IL-24 protein treatment, we cocultured 293M cells or nontransfected HEK-293 (293)
cells with MeWo cells (Fig. 2C). We evaluated the cytotoxic effects of 293M treatment on
melanoma cells using trypan blue exclusion assays. The 293M treatment killed up to 31% of
the MeWo cells, which was comparable to purified MDA7/IL-24 protein killing at various
levels. When MeWo cells were cocultured with 293 cells, only background killing was
observed.
Affinity-Purified and Affinity/Ion Exchange–Purified MDA7/IL-24 Was Cytotoxic and Induced
the Accumulation of Cells in the S phase
We used both affinity-purified and affinity/ion exchange–enriched MDA7/IL-24 protein
preparations to perform functional studies (Fig. 3). We first showed that both affinity-purified
and affinity/ion exchange–enriched MDA7/IL-24 considerably increased the number of cells
arrested in the S phase (Fig. 3A, 3B). Blockade of both affinity-purified and affinity/ion
exchange–purified MDA7/IL-24 with an anti–MDA7/IL-24 neutralizing antibody inhibited
this effect. We further analyzed whether this effect correlated with cytotoxicity in melanoma
cells. We then demonstrated that affinity/ion exchange–purified MDA7/IL-24, compared with
a similar concentration of affinity-purified MDA7/IL-24, was cytotoxic to melanoma cells
(Fig. 3C, 3D). Although affinity-purified MDA7/IL-24 induced up to 18% killing and 27%
apoptosis in melanoma cells, affinity/ion exchange–purified MDA7/IL-24 induced up to 22%
killing and 34% apoptosis in MeWo cells.
MDA7/IL-24 Induced IFN Beta Secretion in Melanoma Cells, and IFN Beta Blockade Partially
Diminished MDA7/IL-24–Induced Cell Death
We then explored the mechanism by which MDA7/IL-24 induced cell death in melanoma cells.
We previously reported that MDA7/IL-24 down-regulates inducible nitric oxide synthase
(iNOS) in melanoma cells. iNOS has been characterized as a poor prognosis marker for patients
with metastatic disease [9,20]. Our findings demonstrated that MDA7/IL-24 causes an inverse
modulation of IRF-1 and IRF-2, the expression of which is directly regulated by exogenous
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IFNs. We also reported previously that MDA7/IL-24 induces phosphorylation of STAT3
[19], which is one of the essential signaling molecules of IFNs in response to extracellular
stimuli.
We next initiated studies of the role of IFNs in the MDA7/IL-24 pathway. IFN beta induces
apoptosis in melanoma [21,22] and causes prolongation of cell-cycle progression via the
accumulation of cells in the S phase [23] and up-regulation of TRAIL [23,24]. To test our
hypothesis that the regulation of gene expression in melanoma cells activated by class I IFNs
results in antitumor effects, we exposed melanoma cells to both affinity-enriched and affinity/
ion exchange–enriched MDA7/IL-24 protein preparations and measured the IFN beta in the
culture supernatant by ELISA. We showed that both affinity-purified and affinity/ion
exchange–purified MDA7/IL-24 induced IFN beta secretion from MeWo cells in a dose-
dependent fashion (Fig. 4A, 4B). We then tested whether the neutralization of IFN beta reduces
MDA7/IL-24–induced death of melanoma cells. Figure 5 shows that the cotreatment of MeWo
cells with neutralizing antibody to IFN beta, which also exposed to MDA7/IL-24, inhibited
cell death by at least 50%,p<0.01 (Fig. 5).
Class I IFNs Were Cytotoxic to Melanoma Cells
The roles of IRFs and IFN beta up-regulation in MDA7/IL-24 signaling were the focus of
studies on melanoma response to treatment with this group of cytokines. We therefore exposed
A375 and MeWo cells to both class I and class II IFNs at concentrations of 500 to 1000 U/mL
for up to 24 h. To evaluate the proliferative effects of IFN treatment on melanoma cells, we
investigated the killing of melanoma cells by using trypan blue exclusion assays (Fig. 6) and
showed that class I IFNs induced cell killing and inhibited proliferation in A375 cells (Fig.
6A). Figure 6B shows that MeWo cells were more resistant to IFN alfa–induced killing and/
or inhibition of proliferation, whereas IFN beta successfully induced cell killing. Moreover,
we were able to compare the biologic effects of IFN gamma with those of IFNs alfa and beta
in melanoma cell lines. To this end, we exposed melanoma cell lines to IFN gamma and
evaluated the proliferative effects of the treatment. Our results demonstrated that melanoma
cell proliferation is greatly induced by IFN gamma, as opposed to the cell death induced by
IFNs alfa and beta (P=0.007, P=0.001, respectively).
MDA7/IL-24 Differentially Regulated Gene Signaling and Apoptosis
We performed microarray analyses in three pathways (apoptosis, MAPK, and signal
transduction, including 96 genes each) to evaluate gene regulation by MDA7/IL-24. These
analyses revealed that apoptotic pathway markers, including caspases and TRAIL, along with
cell-cycle regulators were up-regulated in both normal human epidermal melanocytes and
MeWo cells (Fig. 7A). Down-regulated genes included tumor growth markers such as iNOS,
Cox-2, p38 MAPK, and IRF-1. We repeated these experiments five times in both MeWo and
A375 cells after treatment with MDA7/IL-24. Moreover, cells were either treated with affinity-
purified proteins or cocultured with 293M cells to compare gene regulation using the same
pathway arrays. All treatment conditions identified the same genes that were regulated by
MDA7/IL-24 independent of the protein source. However, treatment of normal human
epidermal melanocytes with these preparations did not identify any genes that were down-
regulated in MeWo cells, such as IRF-1, iNOS, Cox-2, and hsp90.
MDA7/IL-24 Induced TRAIL-R2 in Human Melanoma Cells
We confirmed our findings from the gene array studies with immunoblotting experiments.
Figure 7B shows a group of apoptotic markers after treatment with MDA7/IL-24 protein. Initial
experiments with affinity-purified MDA7/IL-24 protein revealed caspase-3 and procaspase-8
up-regulation with 100 ng/mL of protein rather than with a higher concentration (300 ng/mL).
We observed a similar effect on PARP cleavage, but PI3K inhibition occurred at higher
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concentrations of MDA7/IL-24. We showed that the neutralizing antibody to MDA7/IL-24
reversed this effect. Our coculturing experiments of MeWo cells with 293M cells showed both
Fas and FasL up-regulation and PARP cleavage in the cells cocultured with 293M cells
compared with MeWo controls. Caspase-3 and -9 and procaspase-8 up-regulation in treated
293M cocultures was considerable compared with that in control 293 cells.
We further analyzed TRAIL-R1 (DR4) and TRAIL-R2 (DR5) expression in melanoma cells
treated or not treated with MDA7/IL-24. Figure 8A shows that both DR4 and DR5 expression
were up-regulated in MeWo cells after treatment with affinity-purified MDA7/IL-24. We
confirmed our results on TRAIL-R1 and -R2 expression by cytochemical analysis, which we
performed concurrently with the immunoblotting experiments. DR4 up-regulation was modest
and resulted in increased expression primarily in the cytosol. In contrast, DR5 expression was
strongly up-regulated and localized to plasma membrane.
Discussion
Here, we described a novel pathway of MDA7/IL-24 regulation of apoptosis in melanoma
tumors via endogenous IFN beta induction followed by IRF regulation and TRAIL/FasL
system activation.
The treatment of metastatic melanoma remains a major clinical challenge. Malignant
melanomas are characterized by high intrinsic resistance to chemotherapy and thus, single-
agent or combination chemotherapies do not improve overall survival rates. In recent years,
biochemotherapeutic approaches have resulted in overall higher responses, but their effect on
overall survival has been disappointing. Research to increase our knowledge of the cellular
mechanisms precipitating and modulating neoplasia is critical for the treatment of melanoma.
The detection of cellular targets and pathways for individualized treatment modalities is
therefore crucial.
We previously showed that melanocytes endogenously express MDA7/IL-24 protein, although
its expression is down-regulated during the progression of melanoma [25,26]. Initial studies
with Ad-mda7/IL-24 showed potent growth suppression and apoptosis induction in many
different tumor types, including melanoma, glioblastoma, osteosarcoma, and carcinomas of
the breast, colon, lung, cervix, kidney, and prostate, but not in any normal cells [27,28].
Subsequent mechanistic studies demonstrated that MDA7/IL-24 can induce apoptosis at
various levels such as activating the caspase cascade and up-regulating p53, Bax, TRAIL, and
cell growth arrest [27]. We and others also showed that additional mechanisms for MDA7/
IL-24–mediated cell killing include the regulation of iNOS and MAPK in melanoma [4,9].
Thus, MDA7/IL-24 exerts its tumor-suppressive effects via different signaling pathways in
melanoma, which could also initiate a secondary line of cytokine activation or interactions.
Early events in class I IFN signaling include tyrosine phosphorylation of the IFN receptor
subunits and activation of signaling cascades including IRFs. Recent studies have suggested
that apoptosis is very important for the direct antitumor effect observed after IFN beta treatment
in melanoma cells [24]. However, the precise molecular mechanisms that regulate the direct
effect of IFN beta, including apoptosis, are still only partially understood.
One possible approach to this pathway in melanoma, which we showed previously, is that
MDA7/IL-24 protein activates phosphorylation of STAT3 and down-regulates IRF-1 while
up-regulating IRF-2. Thus, we hypothesized that receptor engagement by MDA7/IL-24
activates STAT3 to bind to the IRF-2 promoter, which in turn competes with IRF-1 binding
to IFN gamma activation cascade molecules, blocking iNOS gene expression. It is well known
that IFN gamma is a major inducer of iNOS in various systems and that the induction of IRF-1
activity by IFN gamma mediates the binding to the iNOS promoter [29]. This pathway
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positively cooperates with STAT-1a activation for the induction of the iNOS promoter [30].
In murine macrophages, discovering the essential role of the IRF-1 binding site for the
induction of the iNOS promoter revealed that the binding of IRF-1 in protein complexes takes
place only after IFN gamma incubation [29]. Of note, Coccia et al. [31] reported that the
inhibitory effect of IL-4 on IFN gamma–stimulated iNOS expression in murine macrophages
occurs because of the potentiation of IRF-2 expression and reduced binding of IRF-1 to the
ISRE (Interferon response sequence element). Because we previously showed that iNOS
expression in melanoma correlates with poor survival, we did not evaluate this particular
pathway for any positive effect by IFN gamma.
In this study, we specifically targeted class I IFNs because of their effect on Fas/FasL- and
TRAIL-induced apoptotic pathways in melanoma. TRAIL was originally identified as an IFN-
stimulated gene. Once TRAIL binds to its receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5),
proapoptotic pathways are activated [32]. In several tumor types, including melanoma, the
activity of TRAIL can be enhanced by IFNs, both in vitro and in vivo [33–34]. In melanomas,
IFN beta preferentially induces TRAIL, and this induction is poor in response to IFN gamma
[24]. Strong induction of TRAIL and/or Fas/FasL in response to IFN leads to recruitment and
activation of FADD. FADD has a death-effector domain sequence that activates procaspase-8
and then execution caspases, which results in cell death. The intrinsic pathway is also activated
by caspase-8, which cleaves Bid, leading to Bax oligomerization. This in turn leads to
cytochrome C release from mitochondria and the activation of caspase-9 [34]
In this study, we showed the induction of TRAIL-R2 (DR5) and then subsequent activation of
both intrinsic and extrinsic caspases (first procaspase-8 followed by caspase-3 and then
caspase-9) and then PARP cleavage. This effect was stronger in coculturing experiments with
MeWo cells and MDA7/IL-24–transfected HEK 293 cells than it was with the affinity-purified
MDA7/IL-24 protein exposure.
However, low doses of protein exposure stimulated the caspases and PARP cleavage at
comparable levels that may indicate dose-dependent activation of the pathway. Our results on
this particular pathway correlates with recently published results by Zhao et al. [35] that
demonstrated the antitumor activity of TRAIL and MDA7/IL-24 combined treatment of
colorectal cancer lines with replicating oncolytic adenovirus system. This combination
treatment induces growth suppression and apoptosis in colorectal cancer lines via the activation
of caspases and the release of cytochrome C.
In addition, our coculturing experiment results showed that accompanying Fas/FasL up-
regulation induced an apoptotic cascade in MeWo cells. On the other hand, PI3K inhibition,
which leads to a balanced signal between antiapoptotic and proapoptotic pathways, required a
high amount of protein. Melanoma cells reportedly express constitutively active Akt because
of the loss of the lipid phosphatase gene PTEN, a negative regulator of PI3K [36]. This could
determine TRAIL sensitivity in these cells, which is dependent on the level of Akt. Cells
expressing the highest level of Akt are the most resistant to TRAIL [37]. However, a direct
correlation between Akt activity and resistance to TRAIL signaling remains unsolved in
melanoma. At this point, we believe that MDA7/IL-24–mediated IFN beta induction of the
TRAIL pathway could be controlled by Akt and/or PI3K levels in melanoma cells.
MDA7/IL-24 protein binds two distinct type II cytokine heterodimeric receptor complexes,
IL-20R1/IL-20R2 (type 1 IL-20R) and IL-22R1/IL-20R2 (type 2 IL-20R). In our previous
study [19], we found that although MDA7/IL-24 induces STAT3 activation and cytotoxicity
in melanoma cells, these activities are disengaged, and that STAT3 phosphorylation is not
required for MDA/7/IL-24 receptor–mediated killing. Thus, we concluded that human MDA7/
IL-24 protein kills melanoma cells via an IL-20R–dependent but STAT3-independent
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mechanism. In our current study, we confirmed that IL-20R1 is a required signaling receptor
for killing and apoptosis of melanoma cells by MDA7/IL-24.
In conclusion, this study, to the best of our knowledge, is the first to show that MDA7/IL-24
induces endogenous IFN beta production and secretion leading to melanoma cell growth arrest
and apoptosis. We also identified a series of apoptotic markers, including TRAIL and Fas-FasL
regulation that may mediate this pathway. We thus propose a pathway of MDA7/IL-24
regulation of melanoma apoptosis via IFN beta induction followed by TRAIL/FasL system
activation. We emphasize that the IFNs and their signal transduction pathways could
characterize some of the therapeutic target sites for the MDA7/IL-24–mediated regulation of
cell growth in melanoma.
Acknowledgements
Supported by NIH Grant R41 CA 89778 and P50 CA 93459 (to E.A.G. and S.E.), and The Cancer Foundation for
Melanoma Research (to S.E.).
References
1. Jiang H, Su ZZ, Lin JJ, Goldstein NI, Young CS, Fisher PB. The melanoma differentiation associated
gene mda-7 suppresses cancer cell growth. Proc Natl Acad Sci USA 1996;93:9160–9165. [PubMed:
8799171]
2. Madireddi MT, Su ZZ, Young CS, Goldstein NI, Fisher PB. Mda-7, a novel melanoma differentiation
associated gene with promise for cancer gene therapy. Adv Exp Med Biol 2000;465:239–261.
[PubMed: 10810631]
3. Mhashilkar AM, Schrock RD, Hindi M, Liao J, Sieger K, Kourouma F, Zou-Yang XH, Onishi E, Takh
O, Vedvick TS, Fanger G, Stewart L, Watson GJ, Snary D, Fisher PB, Saeki T, Roth JA, Ramesh R,
Chada S. Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer
gene therapy. Mol Med 2001;7:271–282. [PubMed: 11471572]
4. Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, Valerie K, Dent P, Fisher PB. mda-7
(IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated
overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci USA
2002;99:10054–10059. [PubMed: 12114539]
5. Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K, Mumm JB, Stewart AL, Boquoi
A, Dumoutier L, Grimm EA, Renauld JC, Kotenko S, Chada S. Melanoma differentiation-associated
gene 7/ interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer
Res 2003;63:5105–5113. [PubMed: 12941841]
6. Ramesh R, Ito I, Gopalan B, Saito Y, Mhashilkar AM, Chada S. Ectopic production of MDA-7/IL-24
inhibits invasion and migration of human lung cancer cells. Mol Ther 2004;9:510–518. [PubMed:
15093181]
7. Saito Y, Miyahara R, Gopalan B, Litvak A, Inoue S, Shanker M, Branch CD, Mhashilkar AM, Roth
JA, Chada S, Ramesh R. Selective induction of cell cycle arrest and apoptosis in human prostate cancer
cells through adenoviral transfer of the melanoma differentiation-associated-7 (mda-7)/interleukin-24
(IL-24) gene. Cancer Gene Ther 2005;12:238–247. [PubMed: 15578066]
8. Lebedeva IV, Su ZZ, Chang Y, Kitada S, Reed JC, Fisher PB. The cancer growth suppressing gene
mda-7 induces apoptosis selectively in melanoma cells. Oncogene 2002;21:708–718. [PubMed:
11850799]
9. Ekmekcioglu S, Ellerhorst JA, Mumm JB, Zheng M, Broemeling L, Prieto VG, Stewart AL, Mhashilkar
AM, Chada S, Grimm EA. Negative association of melanoma differentiation associated gene (mda-7)
and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression
in melanoma cells. Mol Cancer Ther 2003;2(1):9–17. [PubMed: 12533668]
10. Gopalan B, Litvak A, Sharma S, Mhashilkar AM, Chada S, Ramesh R. Activation of the Fas-FasL
Signaling Pathway by MDA-7/IL-24 Kills Human Ovarian Cancer Cells. Cancer Res 2005;65:3017–
3024. [PubMed: 15833826]
Ekmekcioglu et al. Page 11
Cytokine. Author manuscript; available in PMC 2009 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
11. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC. Cutting edge: STAT activation by
IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol 2001;167:3545–
3549. [PubMed: 11564763]
12. Wang M, Tan Z, Zhang R, Kotenko SV, Liang P. Interleukin 24 (MDA-7/MOB-5) signals through
two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. J Biol Chem 2002;277:7341–
7347. [PubMed: 11706020]
13. Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, West J, Brandt C, Jelinek L, Madden K, McKernan
PA, Foster DC, Jaspers S, Chandrasekher YA. Interleukins 19, 20, and 24 signal through two distinct
receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions.
J Biol Chem 2002;277:47517–47523. [PubMed: 12351624]
14. Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis
and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003;8(3):
237–249. [PubMed: 12766484]
15. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004;116:205–219. [PubMed:
14744432]
16. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer
therapy. Cytokine Growth Factor Rev 2003;14:337–348. [PubMed: 12787570]
17. Mamane Y, Heylbroeck C, Génin P, Algarté M, Servant MJ, LePage C, DeLuca C, Kwon H, Lin R,
Hiscott J. Interferon regulatory factors: the next generation. Gene 1999;237(1):1–14. [PubMed:
10524230]
18. Mumm JA, Ekmekcioglu S, Poindexter NJ, Chada S, Grimm EA. Soluble human MDA-7/IL-24:
characterization of the molecular form(s) inhibiting tumor growth and stimulating monocytes. J
Interferon Cytokine Res 2006;26(12):877–886. [PubMed: 17238830]
19. Chada S, Mhashilkar AM, Ramesh R, Mumm JB, Sutton RB, Bocangel D, Zheng M, Grimm EA,
Ekmekcioglu S. Bystander Activity of Ad-mda7: Human MDA-7 Protein Kills Melanoma Cells via
an IL-20 Receptor-Dependent but STAT3-Independent Mechanism. Mol Ther 2004;10(6):1085–
1095. [PubMed: 15564140]
20. Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA. Tumor iNOS
predicts poor survival for stage III melanoma patients. Int J Cancer 2006;119:861–866. [PubMed:
16557582]
21. Yoshida J, Mizuno M, Wakabayashi T. lnterferon-β gene therapy for cancer: Basic research to clinical
application. Cancer Sci 2004;95:858–865. [PubMed: 15546502]
22. Nagatani T, Okazawa H, Kambara T, Satoh K, Nishiyama T, Tokura H, Yamada R, Nakajima H.
Effect of natural interferon-beta on the growth of melanoma cell lines. Mel Res 1998;8:295–299.
23. Vannucchi S, Chiantore MV, Fiorucci G, Percario ZA, Leone S, Affabris E, Romeo G. TRAIL is a
key target in S-phase slowing-dependent apoptosis induced by interferon-b in cervical carcinoma
cells. Oncogene 2005;24:2536–2546. [PubMed: 15735750]
24. Chawla-Sarkar M, Leaman DW, Borden EC. Preferential Induction of Apoptosis by Interferon (IFN)-
β Compared with IFN-α2: Correlation with TRAIL/Apo2L Induction in Melanoma Cell Lines. Clin
Cancer Res 2001;7:1821–1831. [PubMed: 11410525]
25. Ekmekcioglu S, Ellerhorst JA, Mhashilkar AM, Sahin AA, Read CM, Prieto VG, Chada S, Grimm
EA. Down-Regulated Melanoma Differentiation Associated Gene (Mda-7) Expression In Human
Melanomas. Int J Cancer 2001;94:54–59. [PubMed: 11668478]
26. Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, Grimm EA. Loss of
MDA-7 Expression With Progression of Melanoma. J Clin Oncol 2002;20(4):1069–1074. [PubMed:
11844832]
27. Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW, Yang HY, Sahin AA,
Hunt KK, Fuson KL, Poìndexter N, Roth JA, Ramesh R, Grimm EA, Mhashilkar AM. MDA-7/IL-24
is a unique cytokine-tumor suppressor in the IL-10 family. Int Immunopharmacol 2004;4:649–667.
[PubMed: 15120650]
28. Fisher PB, Gopalkrishnan RV, Chada S, Ramesh R, Grimm EA, Rosenfeld MR, Curiel DT, Dent P.
Mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene. Cancer Bio Ther 2003;2:24–
38.
Ekmekcioglu et al. Page 12
Cytokine. Author manuscript; available in PMC 2009 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
29. Kleinert H, Schwarz PM, Forstermann U. Regulation of the expression of inducible nitric oxide
synthase. Biol Chem 2003;384(10–11):1343–1364. [PubMed: 14669979]
30. Darville MI, VEizirik DL. Regulation by cytokines of the inducible nitric oxide synthase promoter
in insulin-producing cells. Diabetologia 1998;41:1101–1108. [PubMed: 9754830]
31. Coccia EM, Stellacci E, Marziali G, Weiss G, Battistini A. IFNg and IL-4 differently regulate
inducible NO synthase gene expression through IRF-1 modulation. Int Immunol 2000;12:977–985.
[PubMed: 10882409]
32. Ashkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science 1998;281:1305–1308.
[PubMed: 9721089]
33. Chawla-Sarkar M, Leaman DW, Jacobs BS, Borden EC. IFN-beta pretreatment sensitizes human
melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol 2002;169(2):847–855.
[PubMed: 12097388]
34. Younes A, Kadin ME. Emerging applications of the tumor necrosis factor family of ligands and
receptors in cancer therapy. J Clin Oncol 2003;21(18):3526–3534. [PubMed: 12972530]
35. Zhao L, Dong A, Gu Z, Liu Z, Zhang Y, Zhang W, Wang Y, He L, Qian C, Qian Q, Liu X. The
antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer.
Cancer Gene Therapy 2006;13:1011–1022. [PubMed: 16799468]
36. Li G, Kalabis J, Xu X, Meier F, Oka M, Bogenrieder T, Herlyn M. Reciprocal regulation of MelCAM
and AKT in human melanoma. Oncogene 2003;22(44):6891–6899. [PubMed: 14534536]
37. Bhojani MS, Rossu BD, Rehemtulla A. TRAIL and anti-tumor responses. Cancer Biology and
Therapy 2003;2(4):S71–S78. [PubMed: 14508083]
Ekmekcioglu et al. Page 13
Cytokine. Author manuscript; available in PMC 2009 July 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
A, Purification of MDA7/IL-24 by immunoaffinity chromatography. All samples were
resolved by 12% SDS-PAGE. Lane 1, Heat-denatured, reduced-starting supernatant. Lane 2,
Heat-denaturation and reduced-affinity purification of MDA7/IL-24 performed with resolving
gel (pH 8.9) 0.5 M Tris-HCl. An analysis of MDA7/IL-24 by ELISA showed a 3000-fold
increase in purity over the supernatant. BSA = bovine serum albumin. Lane 3, Western blot
with anti–N-terminal monoclonal of the elution fraction. B, Further purification of MDA7/
IL-24 by immunoaffinity and cation exchange purification. All samples were resolved by 12%
SDS-PAGE (pH 8.32) 1.5 M Tris-HCl. Affinity-purified MDA7/IL-24 was further purified by
cation exchange chromatography. Lane 1, MDA7/IL-24 affinity purified (starting material
loaded onto column). Lane 2, Wash from the column. Lane 3, Elution at 1 M NaCl. Lane 4,
Western blot with anti–N-terminal monoclonal of the elution fraction.
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Figure 2.
A, Affinity-purified MDA7/IL-24 induces cell death in melanoma cells. A panel of melanoma
cells (A375, A375.S2, MeWo, SK-Mel-1, WM35, WM793) was exposed to a dose titration of
affinity-purified MDA7/IL-24 and assessed for cell death by trypan blue exclusion after 5 days.
Cells were analyzed for apoptosis via Annexin V–FITC staining followed by fluorescence-
activated cell sorter analysis. Black bars = percentage of dead cells (trypan blue positive) and
gray bars = percentage of apoptotic cells based on total cells. B, MDA7/IL-24 kills melanoma
cells via ligand binding to type 1 IL-20R. MeWo melanoma cells were exposed to a dose
increase of affinity-purified MDA7/IL-24 and assessed for cell death (cytotoxicity and
apoptosis) after 5 days. Black bars = percentage of dead cells (trypan blue positive) and gray
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bars = percentage of apoptotic cells (by Annexin-V-FITC staining) based on total cells. .Cells
were also treated with antibodies to MDA7/IL-24, IL-20R1 antibody, or IL-22R1 antibody.
MDA7/IL-24 protein was added to antibodies, and cell killing was assessed. Data were plotted
as mean + SD. Error bars represent one standard deviation of the mean. C, MDA7/IL-24–
transfected HEK-293 cells (293M) kill melanoma cells. MeWo melanoma cells were
cocultured with MDA7/IL-24–transfected 293 cells and assessed for cell death after 5 days.
Black bars = percentage of dead cells (trypan blue positive) and gray bars = percentage of
living cells based on total cells. Cells were also cocultured with nontransfected HEK-293 cells
and MeWo cells. Data were plotted as mean + SD. Error bars represent one standard deviation
of the mean.
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Figure 3.
A and B, Purified MDA7/IL-24 induces accumulation of cells in the S phase. A, MeWo
melanoma cells were exposed to a dose titration of affinity-purified MDA7/IL-24 and assessed
by propidium iodide staining for distribution of cells in each cell cycle. B, MeWo melanoma
cells were exposed to a dose titration of affinity/ion exchange–purified MDA7/IL-24 and
assessed by propidium iodide for distribution of cells in each cell cycle. Each arrow indicates
S phase population bars. C and D, Affinity-purified and affinity/ion exchange–purified MDA7/
IL-24 is cytotoxic. C, MeWo melanoma cells were exposed to a dose titration of affinity-
purified MDA7/IL-24 and assessed for cell death by trypan blue exclusion after 5 days. Cells
were analyzed for apoptosis via Annexin V–FITC staining followed by fluorescence-activated
cell sorter analysis. For (C) and (D), black bars = percentage of dead cells (trypan blue positive)
and gray bars = percentage of apoptotic cells based on total cells. Error bars represent one
standard deviation of the mean. D, MeWo melanoma cells were exposed to a dose increase of
affinity/ion-purified MDA7/IL-24 and assessed for cell death after 5 days. Error bars represent
one standard deviation of the mean.
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Figure 4.
MDA7/IL-24-induced interferon (IFN) beta secretion from melanoma cells. A, MeWo cells
exposed to affinity; B, affinity/ion-purified MDA7/IL-24 and supernatants from melanoma
cells treated with affinity-purified and affinity/ion exchange–purified MDA7/IL-24,
respectively, were tested by ELISA after 5 days for IFN beta. Error bars represent one standard
deviation of the mean.
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Figure 5.
Interferon (IFN) beta blockade partially diminishes MDA7/IL-24-induced cell death. MeWo
melanoma cells were exposed to a dose titration of affinity-purified MDA7/IL-24 in the
presence of neutralizing antibodies to IFN beta and assessed for cell death after 5 days. Gray
bars = percentage of living cells, and black bars = percentage of dead cells (trypan blue positive)
based on total cells. Anti-IFN beta–neutralizing antibody was used at 5× molar excess for
predicting the level of IFN beta in supernatant with the IgG control added at the same
concentration. Error bars represent one standard deviation of the mean.
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Figure 6.
Class I (alfa [a] and beta [b]) interferons (IFNs) are cytotoxic to melanoma cells. A, A375
melanoma cells were exposed to a dose titration of both class I and class II (gamma [g]) IFNs
and assessed for cell death after 24 h. For (A) and (B), gray bars = total number of live cells
and black bars = total number of dead cells, trypan blue positive. Error bars represent one
standard deviation of the mean. B, MeWo melanoma cells were exposed to a dose titration of
both class I and II IFN sand assessed for cell death after 24 h. Error bars represent one standard
deviation of the mean.
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Figure 7.
MDA7/IL-24 differentially regulates genes on signaling and apoptosis. A, MeWo melanoma
cells were exposed to either a dose titration of affinity-purified MDA7/IL-24 or cocultured
with MDA7/IL-24–transfected HEK-293 cells. After 48 h of treatment, cells were assessed for
their apoptotic and signaling pathways in gene regulation with commercially available gene
array analysis. B, MeWo melanoma cells were exposed to either a dose titration of affinity-
purified MDA7/IL-24 or cocultured with MDA7/IL-24–transfected HEK-293 cells. After 48
h of treatment, lysates were taken and proteins were precipitated and washed in 1× PBS,
resolved by SDS-PAGE, transferred to nitrocellulose, and Western blotted for apoptotic and
signaling pathway markers
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Figure 8.
MDA7/IL-24 induces tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)–
receptor 2 (TRAIL-R2 or DR5) in human melanoma cells. A, MeWo melanoma cells were
exposed to a dose titration of affinity-purified MDA7/IL-24. After 48 h of treatment, cells were
collected and cytospins prepared for cytochemical assessment of their TRAIL receptor (R1
and R2) expression. (anti-DR4 or anti-DR5, AEC, hematoxylin. Original magnification X400).
B, A second set of identical component were reserved in culture for 48 h of treatment, lysates
were taken, and proteins were precipitated and washed in 1× PBS, resolved by SDS-PAGE,
transferred to nitrocellulose and Western blotted for TRAIL-R1 and R2. MeWo melanoma
cells were exposed to media only (MeWo I), protein preparation media only (MeWo II), and
a dose titration of affinity-purified MDA7/IL-24. After 48 h of treatment, lysates were taken,
and proteins were precipitated and washed in 1× PBS, resolved by SDS-PAGE, transferred to
nitrocellulose and Western blotted for TRAIL-R2.
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